MDCB Credits: 1.00
ARRT Credits: 1.00
Available Until: 10/31/2021
Non-Member Price: $35.00
Member Price: $20.00
Member PLUS Price: $20.00
Once you have exceeded your annual free credit allowance you will be prompted to pay a per-credit fee.
Courses purchased using your credit allowance are non-refundable and need to be completed before their expiration date
View your annual credit allowance here.
Presented by Ross Mitchell, PhD
Artificial Intelligence Officer
Moffitt Cancer Center
From the AAMD Virtual 45th Annual Meeting
July 6 -10, 2020
NOTE: If you earned CE Credits for this session during the AAMD Virtual 45thAnnual Meeting, you will not be eligible to earn CE Credits for it again.
The field of artificial intelligence (AI) is over 60 years old. Recent advances in computational power and biologically inspired artificial neural networks have enabled dramatic breakthroughs. Machines are now able to quickly learn solutions to complex problems previously reserved for human experts. The resulting applications are beginning to transform our lives and societies. AI will also revolutionize cancer care.
This presentation will provide a high-level introduction to machine learning. It will describe the recent breakthroughs and some of the applications transforming our everyday lives. Then it will provide an intuitive glimpse into the inner workings of artificial neural networks to reveal the strengths and limitations of this technology.
Next, it will focus on new and emerging applications in oncology, with an emphasis on medical imaging. For example, several recent studies have used AI for differential diagnosis of disease, to predict patient responses to treatment, and to discover correlations between patterns in medical images and disease-informed genes in a variety of cancers. Finally, this presentation will discuss the caveats of AI applications in oncology, and glimpse ahead to predict future developments in the field.
1. Describe the differences between AI, Machine Learning and Deep Learning
2. Describe several applications of AI in oncology
3. Describe future applications of AI in oncology, and radiotherapy in particular
Educational Level: Entry Level
Dr. Mitchell earned a B.Sc. (Honors) degree in Computer Science (High Honors) from the University of Regina, Canada in 1986. He then completed an M.Sc. in Computer Science through a joint program between the University of Regina and the Allan Blair Cancer Center, in 1989. He went on to complete a Ph.D. in Medical Biophysics at Western University in London Ontario Canada, in 1995. He started post-doctoral studies at the London Health Sciences Center in London Ontario in 1996, then joined Western University as an Assistant Professor in the Department of Medical Biophysics in 1998. He moved to the Department of Radiology at the University of Calgary, Canada in 2000. He was promoted to Associate Professor in 2003, then to Full Professor in 2010.
During his time in Calgary Canada he co-founded Calgary Scientific Inc. (now PureWeb Inc.) where he was also Chief Scientist. PureWeb’s mobile tele-radiology product ResolutionMD was initially created in Dr. Mitchell’s lab. It was the first mobile radiology app to receive regulatory clearance for diagnostic use. It is now available in 13 languages and installed in over 2,500 healthcare facilities across 40 countries worldwide. From 2008 through 2011 Dr. Mitchell was a Fellow with one of Canada’s premiere artificial intelligence laboratories, the Alberta Machine Intelligence Institute at the University of Alberta. He was recruited to Mayo Clinic in Arizona as a Professor of Radiology in 2011 to build a program in Medical Imaging Informatics.
Dr. Mitchell’s research is focused on artificial intelligence, machine learning and deep learning in medicine, with specific applications in medical imaging. He has over 200 publications, including 20 patents, in applied mathematics, biomedical engineering, computer science, radiology, neurology and oncology. He is one of four Principal Investigators of a $3.6M grant from the U.S. National Cancer Institute, designed to unravel the connections between medical imaging, genomics and disease progression in brain cancer.
Dr. Mitchell became Moffitt Cancer Center’s inaugural Artificial Intelligence Officer in 2019. In this role, he will dedicate 60% of his time to leading the cancer center’s efforts to develop digital tools that utilize artificial intelligence and other advanced technologies to improve the efficiency and quality of cancer care. Dr. Mitchell is also a senior member of Moffitt’s Department of Biostatistics and Bioinformatics. In this role, he will spend 40% of his time collaborating with fellow research faculty to enable projects utilizing artificial intelligence.